



nidn10314.ST25  
SEQUENCE LISTING

<110> Klaveness, Jo  
Rongved, Pal  
Hogset, Anders  
Tolleshaug, Helge  
Cuthbertson, Alan  
Godal, Aslak  
Hoff, Lars  
Gogstad, Geir  
Bryn, Klaus  
Naevestad, Anne  
Lovhaug, Dagfinn  
Hellebust, Halldis  
Solbakken, Magne

<120> Diagnostic/Therapeutic Agents

<130> NIDN-10314

<140> 10/734,730

<141> 2003-12-15

<150> 09/925,715

<151> 2001-08-10

<150> 08/959,206

<151> 1997-10-28

<150> 60/049,263

<151> 1997-06-07

<150> 60/049,264

<151> 1997-06-06

<150> 60/049,266

<151> 1997-06-07

<160> 20

<170> PatentIn version 3.1

<210> 1

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Heparin sulphate binding peptide

<400> 1

Lys Arg Lys Arg

1

<210> 2

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fibronectin peptide

nidn10314.ST25

<400> 2

Trp Gln Pro Pro Arg Ala Arg Ile  
1 5

<210> 3

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Lipopeptide consisting of heparin sulphate binding peptide and fibronectin peptide

<220>

<221> MOD\_RES

<222> (1)..(1)

<223> Dipalmitoyl-lysine

<400> 3

Lys Lys Arg Lys Arg Trp Gln Pro Pro Arg Ala Arg Ile  
1 5 10

<210> 4

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic RGDC sequence

<400> 4

Arg Gly Asp Cys  
1

<210> 5

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic fusion peptide comprising a PS binding component and a fibronectin peptide sequence

<400> 5

Phe Asn Phe Arg Leu Lys Ala Gly Gln Lys Ile Arg Phe Gly Gly Gly  
1 5 10 15

Gly Trp Gln Pro Pro Arg Ala Ile  
20

<210> 6

<211> 6

nidn10314.ST25

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Biotinylated endothelin-1 peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> Biotin-D-Trp

<400> 6

Trp Leu Asp Ile Ile Trp  
1 5

<210> 7  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Biotinylated fibrin-antipolymerant peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> Biotin-Gly

<220>  
<221> MOD\_RES  
<222> (10)..(10)  
<223> AMIDATION

<400> 7

Gly Pro Arg Pro Pro Glu Arg His Gln Ser  
1 5 10

<210> 8  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Lipopeptide

<220>  
<221> MOD\_RES  
<222> (5)..(5)  
<223> Biotinylated-lys

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> Dipalmitoyl-lysine

&lt;400&gt; 8

Lys Trp Lys Lys Lys Gly  
 1 5

&lt;210&gt; 9

&lt;211&gt; 25

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Biotinylated synthetic oligonucleotide

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)..(1)

&lt;223&gt; Biotinylated

&lt;400&gt; 9

gaaaggtagt ggggtcgtgt gccgg

25

&lt;210&gt; 10

&lt;211&gt; 25

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Biotinylated synthetic oligonucleotide

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)..(1)

&lt;223&gt; Biotinylated

&lt;400&gt; 10

ggcgctgatg atgttggtga ttctt

25

&lt;210&gt; 11

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Lipopeptide containing the RGD sequence and a fluorescein reporter group

&lt;220&gt;

&lt;221&gt; MOD\_RES

&lt;222&gt; (1)..(1)

&lt;223&gt; Dipalmitoyl-lys

&lt;220&gt;

&lt;221&gt; MOD\_RES

&lt;222&gt; (4)..(4)

&lt;223&gt; Acetyl-RGD-K-fluorescein side chain

&lt;400&gt; 11

Lys Lys Lys Lys Gly  
 1 5

&lt;210&gt; 12

&lt;211&gt; 18

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Synthetic endothelial cell binding lipopeptide

&lt;220&gt;

&lt;221&gt; MOD\_RES

&lt;222&gt; (1)..(1)

&lt;223&gt; 2-n-hexadecylstearyl-lysine

&lt;220&gt;

&lt;221&gt; MOD\_RES

&lt;222&gt; (18)..(18)

&lt;223&gt; AMIDATION

&lt;400&gt; 12

Lys Leu Ala Leu Lys Leu Ala Leu Lys Ala Leu Lys Ala Ala Leu Lys  
 1 5 10 15

Leu Ala

&lt;210&gt; 13

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Thiol functionalised lipid molecule

&lt;220&gt;

&lt;221&gt; MOD\_RES

&lt;222&gt; (1)..(1)

&lt;223&gt; Dipalmitoyl-lysine

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (4)..(4)

&lt;223&gt; Acp

&lt;400&gt; 13

Lys Lys Lys Xaa Cys

1

5

<210> 14  
 <211> 4  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic lipopeptide functionalised with captopril

<220>  
 <221> MOD\_RES  
 <222> (1)..(1)  
 <223> Dipalmitoyl-lysine

<220>  
 <221> MOD\_RES  
 <222> (4)..(4)  
 <223> AMIDATION

<220>  
 <221> MOD\_RES  
 <222> (4)..(4)  
 <223> Amide-linked via side chain to captopril

<400> 14

Lys Lys Lys Lys  
 1

<210> 15  
 <211> 13  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic lipopeptide functionalised with captopril

<220>  
 <221> MOD\_RES  
 <222> (1)..(1)  
 <223> Dipalmitoyl-lysine

<220>  
 <221> MOD\_RES  
 <222> (4)..(4)  
 <223> Acp

<220>  
 <221> MISC\_FEATURE  
 <222> (4)..(4)  
 <223> Acp

nidn10314.ST25

<220>  
<221> MOD\_RES  
<222> (13)..(13)  
<223> AMIDATION

<400> 15

Lys Lys Lys Xaa Ile Arg Arg Val Ala Arg Pro Pro Leu  
1 5 10

<210> 16  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Lipopeptide comprising an interleukin  
1 receptor binding peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> Dipalmitoyl-lysine

<400> 16

Lys Gly Asp Trp Asp Gln Phe Gly Leu Trp Arg Gly Ala Ala  
1 5 10

<210> 17  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Core peptide comprising  
dabsylated-atherosclerotic  
plaque binding sequence and RGDS

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> Dabsylated-tyrosine

<220>  
<221> MOD\_RES  
<222> (10)..(10)  
<223> Arg-Gly-Asp-Ser chain linked via NH2 group of lysine

<400> 17

Tyr Arg Ala Leu Val Asp Thr Leu Lys Lys Gly Cys  
1 5 10

<210> 18  
<211> 15

nidn10314.ST25

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Lipopeptide with an affinity  
for thrombi

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> Dipalmitoyl-lysine

<220>  
<221> MOD\_RES  
<222> (15)..(15)  
<223> AMIDATION

<400> 18

Lys Asn Asp Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu Gln  
1 5 10 15

<210> 19  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Lipopeptide functionalised with atenolol

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> Dipalmitoyl-lysine

<220>  
<221> MOD\_RES  
<222> (4)..(4)  
<223> AMIDATION

<220>  
<221> MOD\_RES  
<222> (4)..(4)  
<223> Lysine with side chain linked via amide bond to atenolol

<400> 19

Lys Lys Lys Lys  
1

<210> 20  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>



nidn10314.ST25

<223> Description of Artificial Sequence: Lipopeptide containing chlorambucil

<220>

<221> MOD\_RES

<222> (1)..(1)

<223> Dipalmitoyl-lysine

<220>

<221> MOD\_RES

<222> (4)..(4)

<223> Lysine with side chain linked via amide bond chlorambucil

<220>

<221> MOD\_RES

<222> (4)..(4)

<223> AMIDATION

<400> 20

Lys Lys Lys Lys

1